A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells.
Takayuki UenoNorikazu MasudaShunji KamigakiTakashi MorimotoFutoshi AkiyamaMasafumi KurosumiHitoshi TsudaYoshiki MikamiSunao TanakaSatoshi MoritaMasakazu ToiPublished in: Cancer medicine (2018)
UMIN000001331 Phase II study of neoadjuvant letrozole combined with low-dose metronomic cyclophosphamide for postmenopausal women with endocrine-responsive breast cancer (JBCRG-07).
Keyphrases
- low dose
- phase ii study
- locally advanced
- estrogen receptor
- positive breast cancer
- rectal cancer
- high dose
- endothelial cells
- polycystic ovary syndrome
- bone mineral density
- open label
- breast cancer risk
- squamous cell carcinoma
- radiation therapy
- early breast cancer
- lymph node
- placebo controlled
- postmenopausal women
- cancer therapy
- double blind
- cross sectional
- type diabetes
- insulin resistance
- high glucose
- body composition
- drug delivery
- vascular endothelial growth factor
- skeletal muscle